Personalized medicine, population genetics and privacy : an empirical study of international gene banks

The promise of personalized medicine lies in its potential to fundamentally change healthcare. In the past, pharmaceuticals were prescribed on a "one size fits all" basis-patients with certain disease phenotypes were given what were thought to be appropriate drugs. There is growing evidence however that the effectiveness of these drugs may differ by individual and by sub-group; presumably due to fundamental genetic differences in disease and metabolic pathways. Drugs like Herceptin, Gleevec and Iressa are part of an emerging trend in the biopharmaceutical arena of drugs that are accompanied by genetic diagnostic tests and prescribed only for patients with genotypes in which the agents are most effective.

Department dc:contributor.department

Management of Technology Program.

Grantor dc:publisher

Massachusetts Institute of Technology

Year dc:date.issued

2005

Author dc:creator

• Holland, Chad D. (Chad Darrel)

Advisor dc:contributor.advisor

• Fiona E. Murray and Anthony J. Sinskey.

• Harvard University--MIT Division of Health Sciences and Technology.
• Management of Technology Program.

Statement dc:rights

• M.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.

Licence dc:rights.uri

• http://dspace.mit.edu/handle/1721.1/7582

Language dc:language.iso

eng

Handle dc:identifier.uri

http://hdl.handle.net/1721.1/33089

OAI identifier oai:identifier

oai:dspace.mit.edu:1721.1/33089